Key facts
- This page summarizes Bernard Denoyer's Form 4 filing for OKYO Pharma Ltd (OKYO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Jun 2026, 17:00.
Bernard Denoyer - 08 Jun 2026 Form 4 Insider Report for OKYO Pharma Ltd (OKYO)
- Reporting relationship
- Director
- Issuer ticker
- OKYO
- Reported as of
- 08 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jun 2026, 17:00:07 UTC
- Prior SEC filing
- 02 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bernard Denoyer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Bernard Denoyer filed Form 4 for OKYO Pharma Ltd (OKYO) on 10 Jun 2026.
Change
- Previous filing in this sequence was filed on 02 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001397636
Primary reporting owner
Denoyer Bernard
- Relationship
- Director
- Address
- 14-15 CONDUIT ST, LONDON, UNITED KINGDOM
- Signature
- /s/ Bernard Denoyer
- Signature date
- 10 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OKYO
transaction
Derivative
Option
Award
- Transaction value
- Shares
- +3,500
- Change %
- +11%
- Price
- $1.85*
- Shares after
- 35,190
- Date
- 08 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 3,500
- Exercise price
- $1.85
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
Options vest 25% per year over four years beginning on the first anniversary of the grant date